MacroGenics Q2 FY26 turns to net income of $19.52 million; revenue more than doubled to $32.83 million
Reuters2026/08/13 20:14- MacroGenics swung to GAAP net income of $19.5 million in Q2 2026 from a net loss a year earlier.
- Revenue more than doubled to $32.8 million, driven by a $24.5 million Sanofi regulatory milestone tied to U.S. TZIELD approval.
- R&D expense edged down to $38.8 million; G&A fell to $7.9 million on lower personnel-related costs.
- Sold GMP drug-substance manufacturing operations to Bora for a $122.5 million base price, receiving $119.6 million cash at closing.
- Pro forma cash and marketable securities totaled $327 million, extending runway guidance through 2028; ESMO 2026 data planned for MGC026 and lorigerlimab.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
